<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463073</url>
  </required_header>
  <id_info>
    <org_study_id>CBI-GBM-01</org_study_id>
    <nct_id>NCT00463073</nct_id>
  </id_info>
  <brief_title>Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas</brief_title>
  <official_title>A Phase II Trial With Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The&#xD;
      activity is limited, with an approximately 15 % response rate and a progression-free survival&#xD;
      of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and&#xD;
      the high-level expression of vascular endothelial growth factor on malignant gliomas, one&#xD;
      would expect synergy between bevacizumab and irinotecan against gliomas. In addition, 40-50 %&#xD;
      of GBM have EGFR amplification/mutation making the EGFR an additional target. By combing&#xD;
      cetuximab, with irinotecan and bevacizumab, one would expect further response, than&#xD;
      irinotecan and bevacizumab alone. In addition, recurrent gliomas have an extremely poor&#xD;
      prognosis, so innovative therapies are needed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">32</enrollment>
  <condition>Malignant Gliomas</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Histological verification of primary GBM&#xD;
&#xD;
          -  Recurrence or progression after standard treatment (debulking surgery of possible,&#xD;
             radiotherapy and temozolamide within last six months)&#xD;
&#xD;
          -  Evidence of measurable recurrent progressive primary GBM (CT/MRI scan)&#xD;
&#xD;
          -  PS 0-2 (ECOG scale)&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Life expectancy &gt; 3 month&#xD;
&#xD;
          -  Normal organ function:&#xD;
&#xD;
          -  Platelets &gt; 125 x 109/l&#xD;
&#xD;
          -  Hemoglobin &gt;6,2 mmol/l&#xD;
&#xD;
          -  Leukocytes &gt; 3 x 109/l&#xD;
&#xD;
          -  ACN&gt; 1,5 x 109/l&#xD;
&#xD;
          -  ASAT and/or ALAT &lt; 3 x upper normal limit&#xD;
&#xD;
          -  Bilirubin &lt; 1,5 x upper normal limit&#xD;
&#xD;
          -  Creatinine clearance &gt; 45 ml/min&#xD;
&#xD;
          -  Creatinine &lt; 1,5 x upper normal limit&#xD;
&#xD;
          -  APTT &lt; normal limit&#xD;
&#xD;
          -  INR &lt; normal limit&#xD;
&#xD;
          -  Cholesterol &lt; 7 mmol/l&#xD;
&#xD;
          -  Fertile females must use oral contraceptive, IUD (intrauterine device) or&#xD;
             preservatives. Fertile males must use preservatives.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Radiotherapy or chemotherapy within the last 4 weeks.&#xD;
&#xD;
          -  Co-medication that may interfere with study results; e.g. immunosuppressive agents&#xD;
             other than corticosteroids&#xD;
&#xD;
          -  Prior EGFR- or VEGFR- based therapy.&#xD;
&#xD;
          -  Any condition (medical, social, psychological), which would prevent adequate&#xD;
             information and follow-up&#xD;
&#xD;
          -  Any other active malignancy or previous malignancies within the last 5 years, except,&#xD;
             adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ.&#xD;
&#xD;
          -  No hypercholesterolemia or hypertriglyceridemia (despite lipid-lowering therapy).&#xD;
&#xD;
          -  Any significant cardiac disease (New York Heart Association Class II or greater),&#xD;
             arrhythmia, congestive heart failure, acute myocardial infarction within 6 months or&#xD;
             unstable angina pectoris.&#xD;
&#xD;
          -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  Evidence of bleeding diathesis, coagulapathy or taking ASA, NSAIDs or clopidogrel&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to day 0, anticipation of need for major surgical procedure during the curse of&#xD;
             the study&#xD;
&#xD;
          -  Minor surgical procedures, fine needle aspirations or core biopsies within 7 days&#xD;
             prior to day 0&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess&#xD;
             within 6 month prior to day 0&#xD;
&#xD;
          -  History of known HIV, Hepatitis B and Hepatitis C negative&#xD;
&#xD;
          -  Any ongoing infection, uncontrolled diabetes mellitus, serious non-healing wound,&#xD;
             ulcer or bone fracture&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Requires therapeutic anti-coagulation&#xD;
&#xD;
          -  Blood pressure &gt; 150/100 mmHG&#xD;
&#xD;
          -  Grade 2 or greater proteinuria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrik Lassen, MD., PH.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Dept. of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>April 19, 2007</study_first_submitted>
  <study_first_submitted_qc>April 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <last_update_submitted>December 10, 2008</last_update_submitted>
  <last_update_submitted_qc>December 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2008</last_update_posted>
  <keyword>Progressive primary Glioblastoma multiforme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

